Harmony Biosciences Holdings Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $40.60 on 10/29/24, while the lowest price for the same period was registered at $19.03 on 10/30/23.
52-week price history of HRMY Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Harmony Biosciences Holdings Inc’s current trading price is 2.19% away from its 52-week high, while its distance from the 52-week low is 118.02%. The stock’s price range during the 52-week period has remained between $19.03 and $40.60. In the Healthcare sector, the company’s shares saw a trading volume of around 1.32 million for the day, which was evidently higher than the average daily volume of 0.45 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Harmony Biosciences Holdings Inc (HRMY) has experienced a quarterly rise of 22.53% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.36B and boasts a workforce of 246 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 34.39, with a change in price of +10.97. Similarly, Harmony Biosciences Holdings Inc recorded 448,976 in trading volume during the last 100 days, posting a change of +35.94%.
Examining HRMY’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for HRMY stands at 0.41. Similarly, the long-term debt-to-equity ratio is also 0.32.
HRMY Stock Stochastic Average
Harmony Biosciences Holdings Inc’s raw stochastic average for the past 50 days is presently 98.54%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 98.54%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 48.96% and 26.51%, respectively.
HRMY Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The metric has seen a significant gain of 28.45% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 34.23%. Over the past 30 days, the price of HRMY has fallen by 3.73%. And in the last five days, it has surged by 19.02%.
